1	
2	Effect of extended cefquinome treatment on clinical persistence or recurrence of environmental
3	clinical mastitis
4	
5	
6	
7	J. M. Swinkels ^{a*} , T. J. G. M. Lam ^{a, b} , M. J. Green ^c , and A. J. Bradley ^{c, d}
8	
9	^a GD Animal Health Service, Deventer, The Netherlands,
10	
11	^b Department of Farm Animal Health, Faculty of Veterinary Medicine, Utrecht University, The Netherlands
12	
13	^c University of Nottingham, School of Veterinary Medicine and Science, Leicestershire, United Kingdom
14	
15	^d Quality Milk Management Services Ltd., Wells, Somerset, United Kingdom
16	
17	
18	* Corresponding author. Tel: +31-651532957
19	E-mail: f.zwaal@kpnplanet.nl (J.M. Swinkels)
20	
21	
22	
•••	
23	
24	
25	

26 Abstract

27

28 The efficacy of antibiotic treatment of clinical mastitis (CM) is classically evaluated using 29 bacteriological cure. This provides a concise and objective way of assessing efficacy, but unfortunately 30 does not reflect the field situation where persistence or recurrence of clinical signs lead to perceived 31 treatment failure. If clinical signs persist or recur, intramammary (IMM) treatment is often extended or 32 supplemented with parenteral treatment, in the expectation of a more efficient elimination of clinical 33 signs or a lower probability of recurrence of clinical signs. The objective of this study was to evaluate 34 the efficacy against clinical persistence or recurrence of three cefquinome treatment regimes, standard 35 1.5-day intramammary (SIMM), 5-day extended intramammary (EIMM) and combination of EIMM 36 plus 5-day extended parenteral (ECOMBO) treatment. The study was conducted on three dairy farms 37 with a high recurrence rate of environmental mastitis. Efficacy was evaluated using a multi-level model 38 at the quarter and at the cow level, based on the persistence or recurrence of clinical signs at any time 39 during a 105-day period following the end of the initial treatment, independent of pathogen. The most 40 prevalent pathogens were E. coli (16.9%) and S. uberis (11.97%). EIMM and ECOMBO significantly 41 decreased the persistence or recurrence of CM by 8 % and 6 % at the quarter level and by 9 % and 8 % 42 at the cow level, respectively. ECOMBO may not reduce the persistence or recurrence of CM beyond 43 EIMM. Whilst extended treatment regimens offered an improved outcome in this study, the producer 44 and practitioner need to carefully consider such regimens from the perspective of prudent antibiotic use. 45

46 *Keywords*: Bovine; Lactation; Mammary gland; Extended treatment; Antibiotic

48 Introduction

49 Environmental pathogens, particularly *Streptococcus uberis* and *Escherichia coli*, can be a cause 50 of persistent intramammary infection (Van Eennenaam et al., 1995, Döpfer et al., 1999, Bradley and 51 Green, 2001). On some farms, with a low bulk milk somatic cell count (**BMSCC**) and high incidence of 52 clinical mastitis (CM), a significant proportion of CM may occur in a limited number of animals as a 53 result of a high level of recurrence (Houben et al., 1993, Lam et al., 1996, Zadoks et al., 2001). 54 Recurrent CM cases have been described as being as severe as index cases, with comparable impact on 55 milk yield and probability of death (Bar et al., 2007). Moreover, cows with recurrent CM are at a higher 56 risk for culling (Bar et al., 2008).

57

Recurrent CM is usually defined by initial disappearance and subsequent re-occurrence of clinical signs after a preset number of days. Using this definition, recurrent CM can be due to a recrudescence of a persistent IMM infection due to failure to cure (Pinzón-Sánchez et al., 2011), or as a result of re-infection of the quarter after successful cure. However, differentiating between persistence of infection and re-infection is not possible in the field. Generally, in practice, the disappearance of clinical signs is considered as cure, whereas persistence or recurrence of clinical signs is considered as treatment failure. This treatment failure is what is evaluated in this study.

65

One of the consequences of successful elimination of the causative bacteria is a shortened timeframe during which infection can spread to other cows in the herd, via the milking machine, the milker or the environment. Potentially, improving bacteriological cure rates decreases the infection pressure on healthy cows and, thus, prevents new CM cases. At the same time bacteriological cure also

- prevents the recrudescence of persistent infections (Van Eenennaam et al., 1995). These indirect effects
 of cure may play a role in decreasing the overall incidence of CM.
- 72

73 A number of approaches to improve bacteriological cure of CM have been evaluated, such as 74 extending treatment duration (Sol et al., 2000, Oliver et al., 2004, Milne et al., 2005) and additional 75 parenteral therapy (Shpighel et al., 1997, Erskine et al., 2002, Wenz et al., 2005). However, such studies 76 have not evaluated the long-term outcome of treatment, nor do they necessarily accurately reflect the 77 field situation where CM treatment outcomes are assessed by the elimination of clinical signs, such as 78 abnormal milk, swelling or redness of the udder. In the field, if clinical signs persist or recur, 79 intramammary (IMM) treatment is often extended or reinstated with parenteral treatment in the 80 expectation of a more effective elimination of clinical signs, leading to the use of additional antibiotic on 81 farm. However, there are few reports on the effects of extended treatment, with or without parenteral 82 treatment, on CM persistence or recurrence.

83

Clinical mastitis can be treated with different types of antibiotics. Cefquinome is a broadspectrum β -lactam antibiotic for the treatment of CM, via the IMM and parenteral routes and is licensed as a combination therapy for *E. coli* mastitis in the UK. Concurrent use of IMM and parenteral cefquinome in CM has been evaluated (Shpigel et al., 1997, Ehinger et al, 2006). In herds in which environmental mastitis predominates, the etiology is necessarily diverse thereby demanding a broadspectrum antibiotic for first treatment of CM in the absence of previous identification of the causative pathogen.

91	The aim of this study was to evaluate the effect of different cefquinome treatment regimes in a
92	field based context on the likelihood of clinical persistence or recurrence of CM in dairy herds with high
93	recurrence rates of environmental mastitis.
94	
95	Material and Methods
96	
97	Farms
98	
99	Three commercial dairy farms in Somerset, UK, were selected on the basis of access to electronic
100	records, a history of a high rate of recurrence of CM and a predominance of environmental mastitis (Table
101	1). CM cases were sampled from August 2009 until November 2010. Monthly milk production, individual
102	cow somatic cell count (SCC) and all CM cases had been recorded for at least 12 months prior to the start of
103	the study. Milking protocols were comparable between farms, post milking teat disinfection, pre-dipping or
104	pre-wiping and inspection for CM was practiced on all farms in all cows throughout lactation. Milking
105	procedures and equipment did not change during the study period. All three farms used blanket antibiotic
106	dry cow treatment.
107	
108	Animals
109	
110	Lactating Holstein Friesian dairy cows with CM in one or more quarters were enrolled. Animal
111	parity, yield, historic SCC, CM history, treatment history and relevant clinical data were recorded
112	contemporaneously onto data capture forms or retrieved from on-farm software.
113	

116 Cows were eligible for the study if they were in good general health and had four functional 117 quarters free from clinically significant udder, teat and teat orifice lesions. Cows were followed for 105 118 days after treatment and when cows were dried off or removed from the herd earlier, right censoring was 119 used. Data from animals that were dried off or removed from the herd due to death or culling were 120 analysed until the day of dry off or removal.

121

122 Treatment allocation

123

Cows were randomly allocated to a treatment group, by the herdspersons based on line numbers. Line numbers were allocated randomly on farm at the moment animals joined the herd. Cows that developed CM were sampled aseptically before treatment, according to their pre-assigned treatment group. When clinical signs did not resolve ('treatment failure') during the 105 day period after the last treatment of an animal's first enrolled clinical case, or if clinical signs disappeared and recurred at any time point during that period, the cows were treated again with the same treatment regime on all subsequent occasions.

131

132 Treatment

133

All treatments were administered by farm personnel and three different regimes were evaluated; 135 1) 1.5-day IMM treatment with cefquinome 75 mg (Cobactan LC, MSD Animal Health), twice on the 136 first day, at two consecutive milkings and once, at the morning milking on the following day (SIMM), 137 2) 5-day IMM treatment with cefquinome 75 mg, six times, twice on the first day, at two consecutive
138 milkings, 4 times once a day, at the morning milking (EIMM),

3) 5-day combination treatment with cefquinome 75 mg IMM, six times, twice on the first day at two
consecutive milkings and once, at the morning milking on the following 4 days, plus cefquinome
sulphate suspension (1 mg/kg, Cobactan 2.5%, MSD Animal Health) by intramuscular injection five
times at 24-hour intervals (ECOMBO).

143

144 Post admission withdrawal

145

Animals were withdrawn post admission due to missing data, injury or disability or abnormalities, or concomitant disease or disease other than CM requiring antibiotic or anti-inflammatory treatment.

149

150 Detection of CM, persistence of clinical signs and milk sampling

151

CM was defined as a quarter with any visible change of milk aspect and was identified by farm 152 153 personnel, who had been trained and assessed in the detection, classification and sampling of CM. 154 Individual cases were assessed for persistence or recurrence of clinical signs at every milking (twice 155 daily on two units and thrice daily on one unit). The severity of CM was classified using a three-grade 156 scale: Grade 1, mild (only clots in the milk); Grade 2, moderate (milk aspect changes in colour and / or 157 consistency and / or presence of clots, heat, pain and/or swelling of the udder); and Grade 3, severe 158 (milk aspect changes in colour and / or consistency and / or presence of clots, fever, depression, 159 anorexia, very swollen udder).

Any concurrent treatments were also recorded. Prior to treatment farm personnel collected milk samples from affected quarters. Milk samples were frozen (-20 °C) and collected for submission to the laboratory on a weekly basis.

163

164 Laboratory Methods

165

166 Microbiological investigation and SCC were carried out using the standard milk sample 167 examination techniques, according to the standard recommended by the International Dairy Federation 168 (Bulletin No 132, 1981), International Standard 13366-1:1997 (E) and 13366-2:1997 (G). More specifically, 3 plates were used, 10 µL of secretion was inoculated onto sheep blood agar and Edward's 169 170 agar; 100 µL of secretion was inoculated onto MacConkey agar to enhance the detection of 171 Enterobacteriaceae before incubation at 37 °C. All plates were read at 24, 48, and 72 h. Organisms 172 were identified and quantified using standard laboratory techniques (NMC, 1999; Ouinn et al., 1994). 173 Escherichia coli was identified by colony morphology, oxidase, and indole tests; other 174 Enterobacteriaceae were identified using a microtube identification system (RapiD 20 E, bioMérieux, 175 Basingstoke, UK).

176

177 *Efficacy of treatment*

178

Treatment was considered effective if clinical signs had resolved after the last treatment and did not recur in the 105 day period after treatment, independent of the bacteria involved. To allow assessment of the potential benefits of systemic treatment on concurrently infected (but not clinically affected) quarters, efficacy was assessed at the quarter and cow level. At the quarter level, lack of efficacy was based on clinical persistence or clinical recurrence of CM in the same quarter. At the cow level, lack of efficacy was based on clinical persistence or clinical recurrence of CM in the same cow, irrespective of the quarter involved.

186

187 Data handling and Statistical analysis

188

189 In this randomized, positive controlled, unmasked, three treatment group study, the null 190 hypothesis was that there was no difference in time to clinical recurrence of CM between groups. This 191 hypothesis was analyzed in a multi-level model. The clinically affected quarter was the experimental 192 unit, with the subsequent analysis taking into account the effect of clustering of cases within quarters, 193 and quarters within cows. Inevitably in studies such as this some cows were allocated to treatment group 194 incorrectly. In order to ensure compliance in a large field based study such as this, farmers were allowed 195 some discretion in individual cow treatment allocation. Analysis explored the impact of deviations from 196 the predefined treatment protocols.

197

Cow and farm data were transferred to a database (Microsoft Access 2003) and all fields were checked for unusual or impossible entries. Data fields were coded as categorical or continuous, as appropriate, and data transformations carried out for continuous data to normalize distribution, when necessary.

202

The outcome variable of interest was the persistence or recurrence of clinical signs of mastitis after the end of treatment. Initial analysis consisted of descriptive statistics and graphical assessment. Conventional Kaplan-Meier survival curves were constructed to provide a visual display of clinical

206	persistence or recurrence ('treatment failure') of CM. To construct this curve, the 105 day post treatment
207	study period was divided into 7-day blocks. Each case in each block was coded as recurrent or persistent
208	(CM=1) or not recurrent or persistent (CM=0) at the quarter level. Cows were censored at the end of the
209	105-day follow-up period, at the end of lactation, or after death or culling. Discrete time survival models
210	with random effects were specified so that correlations within the data (cases within quarters and quarters
211	within cows) were accounted for as appropriate in a (frailty) model. The model took the form;
212	
213	$CM_{tijk} \sim Bernoulli probability (mean = \mu_{tijk})$
214	
215	$Logit (\mu_{tijk}) = \alpha + \log t_{tijk} + \log t_{tijk}^2 + \log t_{tijk}^3 + \log t_{tijk}^4 + \beta_1 X_{ijk} + \beta_2 X_{jk} + \beta_3 X_k + u_{jk} + v_k$
216	
217	where t is the week of lactation after previous CM, i, j and k denote the i^{th} CM case in the j^{th} quarter of the
218	k^{th} cow, π_{ijk} the fitted probability of clinical persistence or recurrence of CM after treatment for case i in
219	quarter j of cow k, α the regression intercept, X_{ijk} the vector of covariates at case level, β_1 the coefficients
220	for covariates X_{ik} , X_{jk} the vector of quarter level covariates, β_2 the coefficients for covariates X_{jk} , X_k the

- effects assumed to be normally distributed with mean = 0 and variances Ω_u and Ω_v respectively). 223
- 224

222

225 The distributions of covariates were assessed and transformations or re-categorization carried out 226 as deemed appropriate on biological grounds. Model building was carried out using MLwiN with 227 penalized quasi-likelihood for parameter estimation (Rasbash et al., 2010). To avoid the potential biased estimates that can arise from quasi-likelihood methods (Browne and Draper, 2006) final models were 228

variation between quarters and vk the random effect to reflect residual variation between cows (both random

229	selected using Markov chain Monte Carlo (MCMC) for parameter estimation in WinBUGS
230	(Spiegelhalter et al., 2004) using methods described in detail previously (Green et al., 2004). Covariates
231	remained in the model when the 95% credibility intervals for the odds ratios did not include 1.00.
232	Biologically plausible interactions between significant covariates were tested and included when the
233	95% credibility intervals for the odds ratio of the interaction term did not include 1.00.

Predictions of the survival time to clinical persistence or recurrence of CM after treatment were made using posterior predictive assessments (Gelman et al., 1996, Green et al., 2007). This incorporates the full model posterior predictive distribution, and was used to evaluate model fit and to illustrate the predicted impact of treatment on time to recurrence of CM. The effects of additional treatments were evaluated statistically by including terms for the extra treatments in multivariate models.

240

241 **Results**

242

243 CM occurred in 1008 cases on the three study farms, of which 994, mainly mild to moderate 244 cases, were enrolled (Table 2). Fourteen cases (1008-994) were excluded due to missing data. Ninety-245 three cows were incorrectly allocated to treatment group, 124 received a NSAID concurrently and 106 246 received additional systemic antibiotics. These data were included in the statistical analysis and included 247 as covariates in the initial analysis. There was a large variety of pathogens obtained from the samples 248 and they are listed in Table 3. The most frequently isolated pathogens were E. coli (16.9%) and Strep. 249 *uberis* (12%). These pathogens can be associated with typical environmental CM aetiology which was 250 seen in both first and recurrent cases. Milk production, parity, underlying mastitis pathogens, CM 251 history and treatment history did not differ significantly between groups.

253 Quarter level

254

255 Clinical persistence or recurrence at the quarter level is shown in Table 4. EIMM and ECOMBO 256 treatment reduced the clinical persistence or recurrence of CM by 8% and 6%, respectively (EIMM, 257 OR= 0.38, 95% CI [0.12-0.50] and ECOMBO, OR=0.26, 95% CI [0.19-0.72]). ECOMBO did not 258 further decrease clinical persistence or recurrence when compared to EIMM alone. The time to quarter 259 level clinical persistence or recurrence for the three treatment groups is illustrated in Fig. 1. A posterior 260 prediction of treatment effects is shown in Fig. 2, which is comparable to the survival curve in Fig. 1, 261 demonstrating good model fit, illustrates the predicted outcome for the three treatment groups based on 262 the final model. Other significant covariates for quarter level clinical persistence or recurrence were 263 farm, quarter location, parity and NSAID treatment. Infection severity was not a risk for persistence or 264 recurrence (Table 6).

265

266 Cow level

267

Cow level clinical persistence or recurrence rates are presented in Table 5. The reduction in CM persistence or recurrence was 9% for EIMM and 8% after ECOMBO (EIMM, OR= 0.55, 95% CI [0.38-0.77] and ECOMBO, OR=0.66, 95% CI [0.47-0.93]). The final multivariate model showed that, apart from treatment regime, the significant covariates for clinical persistence or recurrence of CM at the cow level were farm, quarter location, parity, and *Strep. uberis* infection compared to *E. coli* infection (Table 7).

275 Discussion

276

Bacteriological cure is classically used to assess mastitis treatment efficacy because it is a concise and objective parameter. On farm, treatment efficacy is evaluated based on resolution of clinical signs and lack of recurrence. Persistence or recurrence of clinical signs often results in extended intramammary treatment or additional parenteral treatment, expecting a more efficient elimination of clinical signs and/or a lower probability of recurrence of clinical signs.

282

In this study, EIMM and ECOMBO were associated with a significant decrease in the probability of persistent or recurrent CM, both at the quarter level and at the cow level when compared to SIMM, in line with other recent findings (Pinzón-Sánchez et al., 2011). This suggests that extended and more 'aggressive' treatment regimens can be beneficial for individual cows when clinical persistence or recurrence rates are high. A reduction in persistent or recurrent CM can be due simply to higher bacteriological cure after extended treatment (Sol et al., 2000, Oliver et al., 2004, Pinzón-Sánchez et al. 2011), though it could also be as a result of a decrease in the risk of re-infection with another pathogen.

290

Our study differs from earlier studies in that *E. coli* was the most frequently isolated pathogen (Table 3). Döpfer et al. (1999) and Bradley and Green (2001) used molecular methods to demonstrate that clinical *E. coli* mastitis can recur, and that recurrent *E. coli* strains may be cow adapted. We found that *Strep. uberis* CM was nearly twice as likely to clinically persist or recur as *E. coli* CM. We also found a numerical reduction in clinical persistence or recurrence of *E. coli* CM after EIMM compared to SIMM (data not shown), although the difference was not statistically significant. This is in contrast to studies that show that antibiotic treatment of *E. coli* CM should be avoided because it is not effective
(Pyörälä et al., 1998) or not expected to be effective in recurrent cases (Schukken et al., 2004).

299

An often overlooked, indirect effect of increasing bacteriological cure is a lower infection pressure, simply because cured quarters are no longer able to spread infection to other quarters or other cows (Swinkels et al., 2005a, 2005b; Barlow et al., 2009). This means extended treatment may not only result in a higher bacteriological cure but may also have an indirect effect in a herd, such as an overall lower re-infection rate and thus, less persistence or recurrence of CM. Because treatment strategies were compared within herds, the 'infection pressure' for each treatment group was the same and could not have influenced differences between treatment groups.

307

308 Clinical persistence or recurrence of CM was higher at the level of the cow (58%) than the 309 quarter (43%). This was expected, because at the cow level, CM can occur in any of the four quarters. 310 The difference between clinical persistence or recurrence at the cow and quarter level was not large and 311 indicates that the probability of CM recurrence in the other three quarters was relatively low and shows 312 persistence or recurrence mainly occurred in the originally affected quarter. This can be either caused by 313 the fact that chronically infected quarters may 'flare-up' after treatment (Houben et al., 1993, Lam et al., 314 1996, Zadoks et al., 2001) and/or that previously infected quarters are more susceptible to new infection 315 (Zadoks et al., 2001).

316

317 Our model was not built to compare ECOMBO and EIMM treatment directly as both were 318 compared to SIMM. However, we believe ECOMBO treatment was not likely to have reduced 319 persistence or recurrence of CM, at the quarter or cow level, beyond EIMM treatment. In contrast, the 320 probability of clinical persistence or recurrence at the cow level was numerically higher in the 321 ECOMBO group than in the EIMM group (Figure 1). However, it is possible that additional parenteral 322 treatment in the ECOMBO group contributed to removal of subclinical infections (with minor 323 pathogens) in the same cow (Sérievs et al., 2005), making those quarters more susceptible to new 324 infections, thereby increasing the likelihood of subsequent CM and recurrence at the cow level. This is 325 in line with the findings of Wenz et al. (2005), who concluded that parenteral treatment with a 326 cephalosporin in addition to standard IMM cephalosporin treatment had no effect on recurrence of mild 327 E. coli CM. Our results suggest that ECOMBO treatment with certainome may have no added value 328 over EIMM treatment on farms with a high rate of recurrence where environmental pathogens 329 predominate.

330

For quarters in cows with an additional NSAID treatment, clinical persistence or recurrence was significantly higher (Table 6) compared to quarters in cows where NSAID treatment was not used. This is unexpected, because clinical symptoms are assumed to resolve more quickly after NSAID treatment. It may be that farm personnel used additional NSAID treatment in cows which they suspected clinical symptoms to resolve more slowly or which they perceived to be more sensitive to mastitis and thus more likely to recur.

337

Prudent antibiotic use is a pre-requisite in modern agriculture and demands evidence-based justification for extended treatment. Exposure of bacteria to antibiotics increases the risk of selection for antibiotic resistance. EIMM treatment led to increased antibiotic use (from three to six tubes per case) and an increase in the duration of exposure to antimicrobials, which was not compensated by the 8-9% decrease in antibiotics used for recurrent cases. Thus, EIMM treatment led to an overall increase in 343 antibiotic exposure, albeit that that exposure was largely confined to the mammary microbiome. The 344 ECOMBO approach clearly increased antibiotic exposure compared to EIMM, as well as resulting in 345 exposure of the gut flora to antimicrobial activity, and did not seem to lower persistence or recurrence of 346 CM beyond EIMM. This study challenges the perception that additional parenteral treatment will 347 improve the outcome of all CM and re-enforces the need for such approaches to only be used for known 348 pathogens. Whilst research suggests the use of parenteral antibiotics in severe mastitis cases may be 349 helpful (Wenz et al., 2001, Erskine et al., 2002), further research is needed to better define the need 350 and/or criteria for the use of systemic antibiotics in the treatment of mild and moderate cases of CM. 351 352 In conclusion, both EIMM and ECOMBO certain treatment significantly reduced the 353 persistence or recurrence of CM on farms with a high incidence of mild and moderate environmental 354 mastitis. Because additional extended parenteral treatment beyond EIMM may not reduce clinical 355 persistence or recurrence, the producer and practitioner need to carefully consider such regimes from the 356 perspective of prudent antibiotic use.

- 357
- 358 **Conflict of interest statement**
- 359
- 360 The study was sponsored by MSD Animal Health.
- 361

362 Acknowledgement

363

The authors wish to thank Rinse Jan Boersma for his critical comments and Linda Horspool for writingassistance.

367 **References**

368

369	Bar, D., Gröhn, Y.T., Bennett, G., Gonzalez, R.N., Hertl, J.A., Schulte, H.F., Tauer, L.W., Welcome,
370	F.L., Schukken, Y.H., 2007. Effect of repeated episodes of generic clinical mastitis on milk yield in
371	dairy cows. Journal of Dairy Science 90, 4643-4653.

371372

Bar, D., Tauer, L.W., Bennett, G., Gonzalez, R.N., Hertl, J.A., Schukken, Y.H., Schulte, H.F., Welcome,
F.L., Gröhn, Y.T., 2008. The cost of generic clinical mastitis in dairy cows as estimated by using
dynamic programming. Journal of Dairy Science 91, 2205-2214.

Barlow, J.W., White, L.J., Zadoks, R.N., Schukken, Y.H., 2009. A mathematical model demonstrating
indirect and overall effects of lactation therapy targeting subclinical mastitis in dairy herds. Preventive
Veterinary Medicine 90, 31–42.

380

376

Bradley, A.J., Green, M.J., 2001. Adaptation of *Escherichia coli* to the bovine mammary gland. Journal
 of Clinical Microbiology 39, 1845-1849.

383

Browne, W.J., Draper D., 2006. A comparison of bayesian and likelihood-based methods for fitting
multilevel models. Bayesian Analysis 1, 473-514.

Döpfer, D., Barkema, H.W., Lam, T.J.G.M., Schukken, Y.H., Gaastra, W., 1999. Recurrent clinical
mastitis caused by *Escherichia coli* in dairy cows. Journal of Dairy Science 82, 80-85.

389

Ehinger, A.M., Schmidt, H., Kietzmann, M., 2006. Tissue distribution of cefquinome after
intramammary and "systemic" administration in the isolated perfused bovine udder. The Veterinary
Journal 172, 147-153.

393

Erskine, R.J., Bartlett, P.C., VanLente, J.L., Phipps, C.R., 2002. Efficacy of systemic ceftiofur as a
therapy for severe clinical mastitis in dairy cattle. Journal of Dairy Science 85, 2571-2575.

Gelman, A., Meng, X.L., Stern, H., 1996. Posterior predictive assessment of model fitness via realized
 discrepancies. Statistica Sinica 6, 733-807.

399

Green, M.J., Burton, P.R., Green, L.E., Schukken, Y.H., Bradley, A.J., Peeler, E.J., Medley, G.F., 2004.
 The use of Markov chain Monte Carlo for analysis of correlated binary data: patterns of somatic cells in

401 The use of Markov chain Monte Carlo for analysis of correlated binary data. patterns of somatic certs in 402 milk and the risk of clinical mastitis in dairy cows. Preventive Veterinary Medicine 16, 157-174.

403

404 Green, M.J., Bradley, A.J., Medley, G.F., Browne, W.J., 2007. Cow, farm and management factors

405 during the dry period that determine the rate of clinical mastitis after calving. Journal of Dairy Science

406 90, 3764-3776.

- 408 Houben, E.H.P., Dijkhuizen, A.A., van Arendonk, J.A.M., Huirne, R., 1993. Short- and long-term
- 409 production losses and repeatability of clinical mastitis in dairy cattle. Journal of Dairy Science 76, 2561-410 2578.
- 411
- 412 Lam, T.J.G.M., Lipman, L.J., Schukken, Y.H., Gaastra, W., Brand, A., 1996. Epidemiological
- characteristics of bovine clinical mastitis caused by *Staphylococcus aureus* and *Escherichia coli* studied
 by DNA fingerprinting. American Journal of Veterinary Research 57, 39-42.
- 415
- 416 Milne, M.H., Biggs, A.M., Barrett, D.C., Young, F.J., Doherty, S., Innocent, G.T.,
- 417 Fitzpatrick, J.L., 2005. Treatment of persistent intramammary infections with *Streptococcus uberis* in
- 418 dairy cows. Veterinary Record 157, 245-250.
- 419
- NMC, 1999. Laboratory Handbook on Bovine mastitis. National Mastitis Council Inc, Madison, WI.
 421
- 422 Oliver, S.P., Almeida, R.A., Gillespie, B.E., Headrick, S.J., Dowlen, H.H., Johnson, D.L., Lamar, K.C.,
- 423 Chester, S.T., Moseley, W.M., 2004. Extended ceftiofur therapy for treatment of experimentally-induced
- 424 *Streptococcus uberis* mastitis in lactating dairy cattle. Journal of Dairy Science 87, 3322-3329.
- 425
- 426 Pinzón-Sánchez C., Ruegg, P.L., 2011. Risk factors associated with short-term post-treatment outcomes
 427 of clinical mastitis. Journal of Dairy Science 94, 3397-3410.
 428
- 429 Pyörälä S.H., Pyörälä, E.O., 1998. Efficacy of parenteral administration of three antimicrobial agents in
 430 treatment of clinical mastitis in lactating cows. Journal of the American Veterinary Medical Association
 431 212, 407-412.
- 432
- Quinn, P.J., Carter, M.E., Markey, B., Carter, G.R., 1994. Clinical Veterinary Microbiology. Wolfe,
 London, England.
- 435
- Rasbash, J., Browne, W.J., Healy, M., Cameron, B., Charlton, C., 2010. MLwiN Version 2.22. In
 multilevel models project (Centre for multilevel modeling, Bristol).
- 438
- 439 Schukken, Y.H., Dogan, B., Klaessig, S., Simpson, K., Almeida, R., Srinivasan, V., Gillespie, B., Oliver,
- 440 S., 2004. Chronic and recurrent coliforms, implications for lactation therapy. In: Proceedings of the
- 441 Annual Meeting of the National Mastitis Council, pp. 35-40.
- 442
- 443 Sérieys, F., Raguet, Y., Goby, L., Schmidt, H., Friton., G., 2005. Comparative efficacy of local and 444 systemic antibiotic treatment in lactating cows with clinical mastitis. Journal of Dairy Science 88, 93-99.
- 445
- Shpigel, Y., Levin, D., Winkler, M., Saran, A., Ziv, G., Böttner, A., 1997. Efficacy of cefquinome for
 treatment of cows with mastitis experimentally induced using *Escherichia coli*. Journal of Dairy Science
 80, 318-323.
- 449
- 450 Sol, J., Sampimon, O.C., Barkema, H.W., Schukken, Y.H., 2000. Factors associated with cure after
- 451 therapy of clinical mastitis caused by *Staphylococcus aureus*. Journal of Dairy Science 83, 278–284.
- 452

453 Spiegelhalter, D.J., Thomas, A., Best, N., 2004. WinBUGS Version 1.4.1. (Cambridge, UK, MRC
 454 Biostatistics Unit).

455

Swinkels, J.M., Hogeveen, H., Zadoks, R.N., 2005a. A partial budget model to estimate economic
benefits of lactational treatment of subclinical *Staphylococcus aureus* mastitis. Journal of Dairy Science
88, 4273-4287.

459

Swinkels, J.M., Rooijendijk, J.G.A., Zadoks, R.N., Hogeveen, H., 2005b. Use of partial budgeting to
determine the economic benefits of antibiotic treatment of chronic subclinical mastitis caused by *Streptococcus uberis* or *Streptococcus dysgalactiae*. Journal of Dairy Research, 72, 75-85.

463

Van Eenennaam, A.L., Gardner, A., Holmes, J., Perani, J.L., Anderson, R.J., Cullor, J.S., Guterbocks,
W.U., 1995. Financial analysis of alternative treatments for clinical mastitis associated with
environmental pathogens. Journal of Dairy Science 78, 2086-2095.

467

468 Wenz, J.R., Barrington, G.M., Garry, F.B., McSweeney, K.D., Dinsmore, R.P., Goodell, G., Callan,

469 R.J., 2001. Bacteraemia associated with naturally occurring acute coliform mastitis in dairy cows.

- 470 Journal of the American Veterinary Medical Association 219, 976-981.
- 471

472 Wenz, J.R., Garry, F.B., Lombard, J.E., Elia, R., Prentice, D., Dinsmore, R.P., 2005.

473 *Short Communication:* Efficacy of parenteral ceftiofur for treatment of systemically mild clinical

- 474 mastitis in dairy cattle. Journal of Dairy Science 88, 3496-3499.
- 475

476 Zadoks, R.N., Allore, H.G., Barkema, H.W., Sampimon, O.C., Wellenberg, G.J., Gröhn, Y.T.,

- 477 Schukken, Y.H., 2001. Cow- and quarter-level risk factors for *Streptococcus uberis* and *Staphylococcus*
- 478 *aureus* mastitis. Journal of Dairy Science 84, 2649-2663.
- 479

Table 1. The characteristics of the three herds involved in the study

Sumber of dairy cows			
willow of duily comb	560	239	308
BMSCC (x 1,000)	248	201	158
CRM	85	116	76
Predominant Housing	Cubicles	Cubicles /pasture	Cubicles
Predominant Breed	HF	HF	HF
Approx 305 Day Yield (L)	9159	9003	11,309
Ailking Frequency	2X	2X	3X
nastitis (number of quarter of	cases per 100	cows per year).	

526 **Table 2.** Severity of clinical mastitis, indicated in numbers of cases and percentages in parenthesis527

528	Clinical signs	SIMM	EIMM	ECOMBO	Total
529	Grade 1	175 (57)	192 (60)	222 (60)	589 (59)
530	Grade 2	109 (36)	100 (31)	125 (34)	334 (34)
531	Grade 3	21 (7)	26 (8)	24 (6)	71 (7)
532	Total	305 (100)	318 (100)	371 (100)	994 (100)

Grade 1, mild (only clots in the milk); Grade 2, moderate (milk aspect changes in colour and / or consistency and / or presence of clots, heat, pain and/or swelling of the udder); and Grade 3, severe (milk aspect changes in colour and / or consistency and / or presence of clots, fever, depression, anorexia, very swollen udder); SIMM, intramammary cefquinome treatment for 1.5 days; EIMM, extended intramammary cefquinome treatment for 5 days; ECOMBO, extended combined intramammary and parenteral cefquinome treatment for 5 days.

540

541

545				Treat	ment						
546	Diagnosis (n)	SIMN	1	EIMN	M	ECO	MBO	Total		Total ((%)
547	E. coli	54		55		59		168		16.90	
548	S. uberis	31		41		47		119		11.97	
549	S. dysgalactiae	14		13		22		49		4.93	
550	S. aureus	11		17		14		42		4.23	
551	Bacillus spp.	9		14		14		37		3.72	
552	Yeast spp.	14		13		7		34		3.42	
553	Enterococcus spp.	10		8		6		24		2.41	
554	Klebsiella spp.	6		8		3		17		1.71	
555	Prototheca spp.		11		3		1		15		1.5
556	A. pyogenes	2		1		10		13		1.31	
557	Enterobacter spp.	4		2		3		9		0.91	
558	Aerococcus	3		1		4		8		0.80	
559	Pseudomonas spp.	2		3		3		8		0.80	
560	Other major pathogens		8		12		8		28		2.8
561	Any Enterobacterial involvement	76		83		77		236		23.74	
562	Mixed aetiology (major pathogens)	16		22		30		68		6.84	
563	Corynebacterium spp.	17		19		30		66		6.64	
564	Coagulase negative Staph		12		11		30		53		5.3
565	Mixed aetiology (minor pathogens)	9		11		13		33		3.32	
566	Contaminated	11		11		8		30		3.02	
567	No growth	61		53		59		173		17.40	
568	Grand Total	305		318		371		994		100.00)
569											

543 **Table 3**. Aetiology of clinical mastitis cases per treatment group

570 SIMM, intramammary cefquinome treatment for 1.5 days; EIMM, extended intramammary cefquinome 571 treatment for 5 days; ECOMBO, extended combined intramammary and parenteral cefquinome 572 treatment for 5 days.

573

Table 4. Numbers and percentages (between brackets) of persistence or recurrence of clinical mastitis at
 the quarter level within 105 days after the end of treatment of the initial clinical mastitis, irrespective of
 the isolated bacterial species

	,			
Recurrence	SIMM	EIMM	ECOMBO	Total
No (%)	158 (52)	192 (60)	216 (58)	566 (57)
Yes (%)	147 (48)	$126(40)^*$	155 (42)*	428 (43)
Total	305	318	371	994

585 SIMM, intramammary cefquinome treatment for 1.5 days; EIMM, extended intramammary cefquinome 586 treatment for 5 days; ECOMBO, extended combined intramammary and parenteral cefquinome 587 treatment for 5 days; *, The odds ratio (OR) of recurrence after EIMM and after ECOMBO treatment 588 were statistically significantly different from the SIMM treatment group (EIMM, OR = 0.38, 95% CI 589 [0.12-0.50] and ECOMBO, OR=0.26, 95% CI [0.19-0.72].

591 Table 5. Numbers and percentages (between brackets) of persistence or recurrence of clinical mastitis at 592 the cow level within 105 days after the end of treatment of the initial clinical mastitis, irrespective of the 593 isolated bacterial species

595			Treatment		
596	Recurrence	SIMM	EIMM	ECOMBO	Total
597	No (%)	111 (36)	144 (45)	162 (44)	417 (42)
598	Yes (%)	194 (64)	174 (55)*	$209(56)^*$	577 (58)
599	Total	305	318	371	994

600

601 SIMM, intramammary cefquinome treatment for 1.5 days; EIMM, extended intramammary cefquinome 602 treatment for 5 days; ECOMBO, extended combined intramammary and parenteral cefquinome 603 treatment for 5 days; *, the Odds Ratio (OR) of recurrence of EIMM and ECOMBO treatment were 604 statistically significantly different from the SIMM treatment group (EIMM, OR= 0.55, 95% CI [0.38-605 0.77] and ECOMBO, OR=0.66, 95% CI [0.47-0.93].

608				
609	Model term	OR	95%	CI
610	Intercept=-3.2			
611	Ref= SIMM			
612	EIMM	0.26	0.12	0.50
613	ECOMBO	0.38	0.19	0.72
614	$Ref = farm C^*$			
615	Farm H	2.58	1.35	5.32
616	Farm S	0.79	0.36	1.73
617	Ref= quarter LF			
618	Quarter LH	0.66	0.35	1.24
619	Quarter RF	0.49	0.25	0.93
620	Quarter RH	1.08	0.56	2.09
621	Ref=Parity 1			
622	Parity 2	1.31	0.52	3.27
623	Parity 3	3.23	1.25	8.25
624	Parity 4	4.74	1.73	13.17
625	Parity 5+	3.29	1.32	8.26
626	Ref= Grade 1 ^f			
627	Grade 2	1.04	0.63	1.73
628	Grade 3	1.62	0.51	5.23
629	Ref= Yes NSAID ^g			
630	No NSAID	0.30	0.11	0.74

Table 6. Final model outcome of the multivariate analysis of probability of clinical persistence orrecurrence at the quarter level

631

Ref, reference parameter; SIMM, intramammary cefquinome treatment for 1.5 days; EIMM, extended intramammary cefquinome treatment for 5 days; ECOMBO, extended combined intramammary and parenteral cefquinome treatment for 5 days; *, for farm characteristics, see Table 1; LF, left front; RF, right front; LH, left hind; LF, left front; Grade 1, Mild; Only clots in the milk, Grade 2, Moderate; Heat, pain and/or swelling of the udder, Grade 3, Severe; Fever, depression, anorexia, very swollen udder; yes NSAID, non-steroidal anti-inflammatory drug given in addition to antibiotics.

641				
642	Model term	OR	95%	5 CI
643	Intercept= -4.0			
644	Ref= SIMM			
645	EIMM	0.55	0.38	0.77
646	ECOMBO	0.66	0.47	0.93
647	$Ref = farm C^*$			
648	Farm H	1.74	1.22	2.48
649	Farm S	0.90	0.59	1.34
650	Ref=Parity 1			
651	Parity 2	1.80	1.10	3.03
652	Parity 3	3.10	1.85	5.55
653	Parity 4	3.31	1.93	6.10
654	Parity 5+	3.32	2.04	5.71
655	Ref= $E. \ coli^{\dagger}$			
656	S. uberis	1.96	1.21	3.20
657				

Table 7. Final outcome of the multivariate model of the probability of clinical persistence or recurrence
 at the cow level

657

Ref, reference parameter; SIMM, intramammary cefquinome treatment for 1.5 days; EIMM, extended intramammary cefquinome treatment for 5 days; ECOMBO, extended combined intramammary and


parenteral cerquinome treatment for 5 days; *, for farm characteristics, see Table 1; [†], recurrence of


661 clinical mastitis causing pathogen - recurrence of other bacteria was not significantly different from the

662 reference pathogen, *E. coli*.

Figure 1. Legend

Figure 1 Kaplan Meier survival curve, illustrating cumulative survival (=no persistence or recurrence) at
 the quarter level, during 105 days after initial treatment for the 3 different treatment groups






(EIMM) cefquinome treatment for 5 days; ◊, extended combined intramammary and parenteral
cefquinome treatment (ECOMBO) for 5 days.

Both EIMM and ECOMBO treatment reduced persistence or recurrence of clinical mastitis significantly
compared to the SIMM (EIMM, OR = 0.38, 95% CI [0.12-0.50] and ECOMBO, OR=0.26, 95% CI
[0.19-0.72].

Figure 2.

The Bayesian prediction of survival (=no persistence or recurrence) of clinical mastitis after initial
treatment from the multilevel model. The prediction is made for every quarter assuming it could receive
each treatment



X, short intramammary cefquinome treatment (SIMM) for 1.5 days; +, extended intramammary
(EIMM) cefquinome treatment for 5 days; ◊, extended combined intramammary and parenteral
cefquinome treatment (ECOMBO) for 5 days.